Archives

Altesa BioSciences Enrolls First Patient in Phase 2b CARDINAL Clinical Trial Evaluating Vapendavir as Transformational Treatment for Patients with COPD Impacted by Rhinovirus, the Leading Cause of Exacerbations

B Study objective is to demonstrate that treatment with vapendavir can mitigate or prevent worsening of respiratory symptoms caused by rhinovirus, which often lead to… Login to continue reading Login…

Read MoreAltesa BioSciences Enrolls First Patient in Phase 2b CARDINAL Clinical Trial Evaluating Vapendavir as Transformational Treatment for Patients with COPD Impacted by Rhinovirus, the Leading Cause of Exacerbations

Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed

B Organic revenue growth1 of 4% with growth in all operating segments Operating income2 grew 10%, resulting in further margin expansion to 10.1% FME25+ transformation program related… Login to continue reading Login…

Read MoreFresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed

New ASHA-Lantern Texting Program Provides Expert Advice for Handling Picky Eating and Other Feeding Challenges

B Free Program Conveniently Delivers Tips to Caregivers’ Smartphones ROCKVILLE, Md., May 5, 2026 /PRNewswire/ — Feeding challenges are among the most common—and stressful—issues that families… Login to continue reading Login…

Read MoreNew ASHA-Lantern Texting Program Provides Expert Advice for Handling Picky Eating and Other Feeding Challenges

Lilly’s Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years

B In LUCENT-3, more than 60% of patients who achieved disease clearance at one year maintained it after four years of continuous Omvoh treatment Disease… Login to continue reading Login…

Read MoreLilly’s Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years